Regeneron Pharmaceuticals (NASDAQ:REGN) Cut to Equal Weight at Wells Fargo & Company
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) was downgraded by analysts at Wells Fargo & Company from an “overweight” rating to an “equal weight” rating in a research note issued to investors on Friday, Marketbeat reports. They presently have a $580.00 price target on the biopharmaceutical company’s stock, down from their previous price target of […]
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) was downgraded by analysts at Wells Fargo & Company from an “overweight” rating to an “equal weight” rating in a research note issued to investors on Friday, Marketbeat reports. They presently have a $580.00 price target on the biopharmaceutical company’s stock, down from their previous price target of […]
